ST2生物標記市場規模、佔有率和成長分析：按產品類型、生物標記類型、應用、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024年全球ST2生物標記市場價值為46億美元，預計將從2025年的51.8億美元成長到2033年的133.8億美元。預測期（2026-2033年）的複合年成長率預計為12.6%。

全球ST2生物標記市場的主要驅動力是心臟衰竭和心血管風險管理領域對有效預後診斷工具日益成長的臨床需求。 ST2是白細胞介素-1受體家族的成員，已被證實與心肌壓力和纖維化相關，使臨床醫生能夠進行超越傳統利鈉肽的患者分層。主要參與者包括診斷試劑製造商、臨床檢查室和照護現場）開發公司，因為早期準確的風險分層可以降低再入院率。市場成長的核心在於將ST2檢測整合到臨床路徑中，這得益於保險公司的報銷和檢測可及性的提高。此外，人工智慧透過標準化檢測流程並促進ST2結果與電子健康記錄的整合，正在加速ST2檢測的應用，從而改善患者分層和臨床決策。

全球ST2生物標記市場促進因素

免疫檢測技術的最新進展顯著提高了ST2檢測的分析敏感度和特異性，使得臨床和實驗室環境中的測量更加可靠和一致。檢測方法設計的創新簡化了工作流程，最大限度地減少了檢體處理，加速了診斷檢查室和照護現場機構對ST2檢測的採用。這些效能的提升促使臨床醫師將ST2檢測納入診斷流程和病患監測，從而拓展了其應用範圍並增加了市場需求。這些技術進步共同促進了ST2檢測的市場接受度，推動了對ST2檢測研發和商業化的投資，最終惠及整個醫療保健產業。

全球ST2生物標記市場的限制因素

全球ST2生物標記市場面臨許多挑戰，主要原因是創新ST2檢測方法的監管核准流程複雜且不一致。不同司法管轄區之間的差異為開發商帶來了不確定性，阻礙了市場准入，並使商業化進程更加複雜。不同的證據標準和審查程序通常需要大量的臨床檢驗和文件記錄，這增加了產品成功上市所需的時間和資源。因此，小規模的公司可能會猶豫是否進入市場，而成熟的公司則可能專注於法規環境較為簡單的地區，最終限制了新檢測方法的應用，並阻礙了醫療服務提供者可獲得的診斷解決方案的成長。

全球ST2生物標記市場趨勢

在全球ST2生物標記市場中，將其整合到心臟衰竭管理中是一個顯著趨勢。這反映出相關人員日益認同ST2在改善病患預後方面發揮的關鍵作用。臨床醫師擴大將ST2檢測作為綜合心臟衰竭診療路徑中風險分層和治療決策的關鍵要素。這一趨勢的驅動力在於對臨床效用的日益重視。隨著支付者和醫療保健系統要求採用精簡的診療模式以最大限度減少干涉升級，這一趨勢正在加速發展。此外，診斷公司正致力於檢測方法的標準化和工作流程的改進，以確保結果的可靠性並實現與電子健康記錄的無縫整合，從而促進ST2生物標記在心臟護理中的全面應用。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球ST2生物標記市場規模：依產品類型及複合年成長率分類（2026-2033年）

• ST2 ELISA試劑盒
• ST2免疫檢測盒
• ST2快速偵測裝置
• ST2試劑與耗材

全球ST2生物標記市場規模：依生物標記類型及複合年成長率分類（2026-2033年）

• 可溶性ST2 (sST2)
• 膜結合型ST2
• 其他ST2變體

全球ST2生物標記市場規模：依應用及複合年成長率分類（2026-2033年）

• 心血管疾病監測
• 心臟衰竭的預後預測
• 發炎性疾病調查
• 癌症生物標記研究
• 其他診斷和調查用途

全球ST2生物標記市場規模：依最終用戶和複合年成長率分類（2026-2033年）

• 醫院/臨床檢查室
• 診斷中心
• 研究機構
• 生物技術和製藥公司
• 學術機構及教育機構

全球ST2生物標記市場規模：依通路及複合年成長率分類（2026-2033年）

• 直銷
• 批發商和零售商
• 線上銷售

全球ST2生物標記市場規模及複合年成長率（2026-2033年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• Abbott Laboratories
• Roche Diagnostics
• Myriad Genetics
• Siemens Healthineers
• Merck & Co.
• BioMerieux
• Quidel Corporation
• Thermo Fisher Scientific
• QIAGEN
• Ortho Clinical Diagnostics
• Genomic Health
• BMC Diagnostics
• Hologic
• Stryker Corporation
• Illumina
• AscellaHealth
• Epigenomics AG
• LabCorp
• Eurofins Scientific
• Exact Sciences Corporation

結論與建議

Global St2 Biomarker Market size was valued at USD 4.6 Billion in 2024 and is poised to grow from USD 5.18 Billion in 2025 to USD 13.38 Billion by 2033, growing at a CAGR of 12.6% during the forecast period (2026-2033).

The global ST2 biomarker market is primarily driven by the increasing clinical need for effective prognostic tools in heart failure and cardiovascular risk management. ST2, an interleukin-1 receptor family member, is recognized for its ability to correlate with myocardial stress and fibrosis, enabling clinicians to better stratify patients beyond traditional natriuretic peptides. Key players include diagnostic assay manufacturers, clinical laboratories, and point-of-care developers, as early and precise risk stratification reduces hospital readmissions. Central to market growth is the integration of ST2 assays into care pathways, bolstered by reimbursement from payers, thereby enhancing testing accessibility. Additionally, AI is accelerating adoption by standardizing assay workflows and linking ST2 results to electronic health records, improving patient stratification and clinical decision-making.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global St2 Biomarker market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global St2 Biomarker Market Segments Analysis

Global st2 biomarker market is segmented by product type, biomarker type, application, end-user, distribution channel and region. Based on product type, the market is segmented into ST2 ELISA Kits, ST2 Immunoassay Kits, ST2 Rapid Test Devices and ST2 Reagents & Consumables. Based on biomarker type, the market is segmented into Soluble ST2 (sST2), Membrane-bound ST2 and Other ST2 Variants. Based on application, the market is segmented into Cardiovascular Disease Monitoring, Heart Failure Prognosis, Inflammatory Disease Research, Cancer Biomarker Studies and Other Diagnostic & Research Uses. Based on end-user, the market is segmented into Hospitals & Clinical Laboratories, Diagnostic Centers, Research Institutes, Biotechnology & Pharmaceutical Companies and Academic & Teaching Institutions. Based on distribution channel, the market is segmented into Direct Sales, Distributors & Dealers and Online Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global St2 Biomarker Market

Recent advancements in immunoassay technologies have significantly enhanced the analytical sensitivity and specificity for ST2 detection, leading to more reliable and consistent measurements across clinical and research environments. Innovations in assay design have streamlined workflows and minimized specimen handling, facilitating greater adoption among diagnostic laboratories and point-of-care providers. These improvements in performance have encouraged clinicians to integrate ST2 into diagnostic pathways and ongoing patient monitoring, thereby broadening its applications and increasing demand. Collectively, these technological enhancements promote wider acceptance in the market and drive investment in the development and commercialization of ST2 assays, ultimately benefiting the healthcare sector.

Restraints in the Global St2 Biomarker Market

The global ST2 biomarker market faces significant challenges due to the complexities and inconsistencies in regulatory approval pathways for innovative ST2 assays. These discrepancies among different jurisdictions create uncertainty for developers, hindering market entry and complicating the commercialization process. With varying evidentiary standards and review procedures, extensive clinical validation and documentation are often required, which increases both the time and resources needed for successful product launch. As a result, smaller companies may be discouraged from entering the market, while established firms might focus on regions with more straightforward regulatory environments, ultimately limiting the introduction of new assays and restricting the growth of diagnostic solutions available to healthcare providers.

Market Trends of the Global St2 Biomarker Market

The Global ST2 Biomarker market is witnessing a significant trend towards its integration in heart failure management, reflecting a growing consensus among stakeholders on its critical role in improving patient outcomes. Clinicians are increasingly utilizing ST2 measurements as a key element in risk stratification and treatment decision-making within comprehensive heart failure care pathways. This shift is bolstered by the emphasis on clinical utility, as payers and healthcare systems seek streamlined care models that minimize the need for escalated interventions. Furthermore, diagnostic companies are focusing on standardizing assays and refining workflows to facilitate reliable results and seamless integration into electronic health records, thereby enhancing the overall adoption of ST2 biomarkers within cardiology practices.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global ST2 Biomarker Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• ST2 ELISA Kits
• ST2 Immunoassay Kits
• ST2 Rapid Test Devices
• ST2 Reagents & Consumables

Global ST2 Biomarker Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Soluble ST2 (sST2)
• Membrane-bound ST2
• Other ST2 Variants

Global ST2 Biomarker Market Size by Application & CAGR (2026-2033)

• Market Overview
• Cardiovascular Disease Monitoring
• Heart Failure Prognosis
• Inflammatory Disease Research
• Cancer Biomarker Studies
• Other Diagnostic & Research Uses

Global ST2 Biomarker Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinical Laboratories
• Diagnostic Centers
• Research Institutes
• Biotechnology & Pharmaceutical Companies
• Academic & Teaching Institutions

Global ST2 Biomarker Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Distributors & Dealers
• Online Sales

Global ST2 Biomarker Market Size & CAGR (2026-2033)

• North America (Product Type, Biomarker Type, Application, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Biomarker Type, Application, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Biomarker Type, Application, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Biomarker Type, Application, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Biomarker Type, Application, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quidel Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ortho Clinical Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BMC Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AscellaHealth
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epigenomics AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LabCorp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations